Evidence map›Paper›PMID 34755203›Full record

ArticleCancer immunology, immunotherapy : CII2022

Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11-13 2019, Verona, Italy.

Matteo Bellone, Marco Bregni, Vincenzo Bronte, Stefano Ugel, Pier Francesco Ferrucci, Massimo Di Nicola, Paola Nisticò, Gaia Zuccolotto, Antonio Rosato, Vincenzo Russo and 2 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Matteo BelloneUnit of Cellular Immunology, I.R.C.C.S. Ospedale San Raffaele, Milan, Italy.
Marco BregniClinical Trial Center, I.R.C.C.S. Ospedale San Raffaele, Milan, Italy.
Vincenzo BronteImmunology Section, Department of Medicine, University and Hospital Trust of Verona, Verona, Italy.
Stefano UgelImmunology Section, Department of Medicine, University and Hospital Trust of Verona, Verona, Italy.
Pier Francesco FerrucciUnit of Tumor Biotherapy, Department of Experimental Oncology, I.R.C.C.S. European Institute of Oncology, Milan, Italy.
Massimo Di NicolaUnit of Immunotherapy and Anticancer Innovative Therapeutics, Department of Medical Oncology, Fondazione I.R.C.C.S. Istituto Nazionale Tumori, Milan, Italy.
Paola NisticòUnit Tumor Immunology and Immunotherapy, I.R.C.C.S. Regina Elena National Cancer Institute, Rome, Italy.
Gaia ZuccolottoDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Antonio RosatoDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Vincenzo RussoUnit of Immuno-Biotherapy of Melanoma and Solid Tumors, IRCCS Ospedale San Raffaele, Milan, Italy.
Antonio SicaMolecular Immunology Lab, I.R.C.C.S. Humanitas Clinical and Research Center, Rozzano, MI, Italy.
Mario P ColomboMolecular Immunology Unit, Department of Research, Fondazione I.R.C.C.S. Istituto Nazionale dei Tumori, Via Amadeo 42, 20068, Milan, Italy. mariopaolo.colombo@istitutotumori.mi.it.ORCID 0000-0003-0042-7955

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Cancer VaccinesNeoplasmsBiological TherapyHumansImmunotherapyItalyCancer VaccinesAdoptive immunotherapyCancer vaccinesCheckpoint blockade agentsImmunotherapyNIBITTargeted therapies

Identifiers

PMID34755203
PMCPMC8577637

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.